Embodiments described herein relate to a method for preparing cultured cells, the method comprising: obtaining kidney tissue from a human subject; mechanically dissociating the tissue; subjecting the tissue to enzymatic digestion; incubating the tissue with media in a cell culture plate to form cultured cells.

The invention provides method for preparing amnion tissue grafts, as well as the grafts themselves. In specific embodiments, the tissue graft comprises a single layer of dried amnion from an umbilical cord.

Compositions are provided that contain biologically active components of amniotic fluid including growth factors and other proteins, carbohydrates, lipids, and metabolites. The compositions containing biologically active components of amniotic fluid can be useful for a range of therapeutic treatments including joint and soft tissue repair, regulation of skin condition, and for use in organ preservation, such as for use in organ transplant procedures. Advantages of the compositions include that they can be reproducibly produced, without the inherent variability of amniotic fluid from individual donors, and that they are free of fetal waste.

Methods of treating a complex wound by administering to a complex wound in the individual a therapeutically effective amount of a fetal support tissue product to treat the complex wound. Methods of treating a complex lower extremity ulcer by administering to a complex lower extremity ulcer in the individual a therapeutically effective amount of a fetal support tissue product to treat the complex lower extremity ulcer. Methods of reducing or preventing scar formation from granulation tissue by administering a fetal support tissue product to granulation tissue. Methods of repairing a spina bifida defect by administering to the defect in the individual a therapeutically effective amount of an umbilical cord product.

The present invention relates to shaped, bone fiber-based products and methods to make the same.

Decellularized matrix microspheres comprising a polymeric material and a donor tissue are provided. Also disclosed are structures containing a plurality of decellularized matrix microspheres incorporating a first polymer and a donor tissue; and a second polymer, wherein the decellularized matrix microspheres and the second polymer are in the form of a filament. Methods of treating a tissue injury employing the matrix microspheres and structures described as well as their methods of manufacture are also provided.

A sheet structure comprising two joined extracellular matrix (ECM) tissue or sheet layers and a physiological sensor disposed therebetween; the ECM tissue being derived from a mammalian tissue source that includes small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue.

A fetal-origin decellularized nucleus pulposus (NP) allogenic material to regenerate a host's Intervertebral Disc (IVD). The decellularized NP material, obtained from a vertebrate fetus and characterized by comprising high levels of collagen 12 and 14, is used in a pharmacological composition for the treatment of IVD degeneration. The advance is based on the increased ability of the fetal decellularized NP material to stimulate the host constituent cell's to increase the expression of collagen 2 and aggrecan, promoting intrinsic IVD regeneration. A related method includes preparing the pharmaceutical compositions of fetal decellularized material in the form of fragments/microparticles and hydrogel for an injectable mode of administration. The involved material, pharmaceutical compositions and methods may be advantageously used for the prevention and treatment of IVD degeneration and back pain in human and veterinary settings.

Methods and compositions for tissue regeneration of the present invention include a biocompatible porous composite of a decellularized tissue and an aptamer-functionalized hydrogel, wherein the aptamers of the aptamer-functionalized hydrogel specifically and reversibly bind to an active agent.

Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.